Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Chewy Inc (CHWY) vs Cytokinetics Inc (CYTK) Price & Performance

Cytokinetics IncTrade

Price performance (Past 24H)

Key statistics

Chewy Inc vs Cytokinetics Inc — how do they compare? Chewy Inc trades at $22.28 (market cap $9.20B), while Cytokinetics Inc trades at $76.76 (market cap $10.63B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Cytokinetics Inc is trading nearer its 52-week high, Chewy Inc nearer its low. Which is the better fit depends on your goals.

CHWYCYTK
Market Cap
$9.20B$10.63B
Sector
Consumer CyclicalTechnology
52-Week High
$42.33$87.26
52-Week Low
$17.51$34.31
Enterprise Value
$9.16B$10.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Chewy Inc

Chewy (CHWY) trades at $22.59, down 3.99% on the day, reflecting near-term bearish technical pressure. The stock shows strong fundamental progress with revenue climbing to $11.86B in 2025 and net income surging to $392.74M, marking a significant profitability turnaround. Recent earnings beats in Q3 2025 and Q1 2026 contrast with a Q4 2025 miss, indicating volatility. Analyst sentiment remains overwhelmingly positive with an 81.58% buy rating and a $33.82 consensus price target, suggesting substantial upside potential from current levels.

The investment outlook for CHWY is constructive, driven by robust revenue growth, expanding margins, and strong analyst conviction. Key opportunities include the company's dominant position in the pet care e-commerce space and its high customer loyalty through the Autoship subscription model. Primary risks involve competitive pressures from larger retailers, execution challenges in integrating veterinary services, and sensitivity to consumer spending trends. The stock presents a growth opportunity but requires monitoring of quarterly execution against high expectations.

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Returns comparison

Trailing returns across standard periods

About Chewy Inc

Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.

Read more on CHWY

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK